KDventures unit wins US patent allowance for golexanolone in PBC
Umecrine Cognition, a KDventures portfolio company, received a USPTO Notice of Allowance for golexanolone in PBC, with US protection seen until 2042.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
KDventures AB (publ) said its portfolio company Umecrine Cognition has received a Notice of Allowance from the USPTO, the US Patent and Trademark Office. The patent covers the use of golexanolone to treat symptoms of PBC, including fatigue, cognitive problems and itching. The company expects US protection to last at least until 2042.
According to the company, the US accounts for about 70% of the drug's potential market. Phase 1b/2a results are expected in early November 2026. The information was published via TradingView, based on the original press release.
why it matters
For investors, the news concerns intellectual property: the patent extends the period of exclusive rights in the US market, where the company says most of the revenue potential sits. A patent alone does not confirm the drug works, so the clinical readout in early November remains the main catalyst.
tags
instruments
sources
- KDventures AB (publ) (KDV_B) Wins USPTO Allowance for PBC Symptom Treatment With Golexanolone — TradingView, 21 October 2026 at 14:00 UTC
- Umecrine Cognition AB Wins USPTO Allowance for PBC Symptom Treatment Patent — TradingView, 21 October 2026 at 14:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗